Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC

  • Regeneron Pharmaceuticals Inc REGN and Sanofi SA SNY hope to expand Libtayo into a broader population with a chemo combo regimen. 
  • According to data released at the European Society for Medical Oncology 2021 (ESMO21), Libtayo, used on top of platinum doublet chemotherapy, reduced the risk of death by 29% over chemo alone in patients with previously untreated, advanced non-small cell lung cancer (NSCLC).
  • The phase 3 Empower-Lung 3 trial included both squamous and nonsquamous NSCLC patients.
  • Libtayo-chemo hit a median overall survival (OS) of 22 months versus 13 months for the solo chemo group, with a median progression-free survival of 8 months.
  • The Libtayo combo posted a 43% response rate compared with 23% for chemo and a 16-month duration response versus 7 months for chemo. No new Libtayo safety signals were identified.
  • Exploratory analyses showed survival improvements across squamous and nonsquamous histologies and in patients with reduced daily functioning. 
  • In another exploratory analysis, the Libtayo combination helped delay patient-reported quality of life deterioration and pain symptoms.
  • Price Action: REGN stock closed 0.20% lower at $651.88, and SNY stock closed at 0.39% higher at $48.38 on Friday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsESMO21Non-Small Cell Lung CancerPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!